Solid Tumors

Phase I/II Clinical Trial of Radiation Therapy Begins

Published in Cancer Weekly, March 21st, 2000

IBC Pharmaceuticals, LLC, Morris Plains, New Jersey, a joint venture between Immunomedics, Inc. and Beckman Coulter Corp., announced the start of Phase I/II clinical trials of its lead product, Pentacea, for the treatment of solid tumors.

The clinical trial is currently open at two sites in France.

According to Dr. John Reno, IBC Pharmaceuticals, "Pentacea delivers cytotoxic radiation directly to patient's tumors that express carcinoembryonic antigen (CEA). CEA is expressed on most major solid tumors including those of the breast, colon, and lung.

"Pentacea is the first commercial drug to be developed using the company's...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-03-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry